



If you think research is expensive, try disease.

**INVESTMENT IN RESEARCH SAVES LIVES AND MONEY** 

# COVID-19

Coronavirus disease 2019 (COVID-19) is a systemic disease caused by SARS-CoV-2, a novel coronavirus. The virus spreads predominately through respiratory droplets or aerosols, produced when a person sneezes, coughs, or talks. Symptoms appear 2-14 days after exposure and include cough, shortness of breath, sore throat, fever, chills, muscle pain, headache, and loss of taste or smell. However, many people with COVID-19 have no symptoms. Adults with certain underlying conditions (cancer, heart conditions, obesity, and others) are at increased risk of severe illness and death from the virus. Multisystem Inflammatory Syndrome is a rare but serious complication of COVID-19, especially for children. COVID-19 patients. COVID-19 disproportionately affects communities of color. Nationwide, Black people are dying at 1.6 times the rate of white people. While there is currently no cure for COVID-19, scientists are working at record pace to develop COVID-19 treatments and vaccines. COVID-19 vaccination, along with protective measures (hand washing, physical distancing, wearing a mask), are the primary, research-tested ways to protect yourself and your community from getting and spreading COVID-19.

#### TODAY

As of February 8, 2021, more than

463,000

people have died from COVID-19 in the U.S.<sup>9</sup>

COVID-19 patients with underlying conditions such as heart disease, diabetes, and chronic lung disease are

12 times more likely to die. 10

**Approximately** 

**20%** of

asymptomatic people who test positive for COVID-19 remain symptom- free.<sup>11</sup>

### **Research Delivers Solutions**

Widespread testing can help mitigate the spread of COVID-19.<sup>14</sup> The gold standard COVID-19 diagnostic is **polymerase chain reaction (PCR)**, a highly sensitive molecular test that can detect coronavirus genetic material using a small sample. **Antigen tests** are cheaper and generally faster; they are particularly useful for identifying those at or near peak infection and work by detecting viral proteins. **Antibody tests** are used to determine if someone was previously infected with COVID-19 — they are not considered diagnostic tests for identifying active infections. <sup>15,16</sup>

Following intensely vetted research, the FDA has approved vaccines, treatments, and therapeutics for emergency use (EUA) for COVID-19. Recently approved mRNA-based vaccines rely on a technology that is new but has been under development for many years. An injection of a small bit of the virus's genetic code prompts a robust, specific immune reaction. <sup>17</sup> **Remdesivir**, the first FDA authorized COVID-19 treatment, <sup>18</sup> is an antiviral medication that can shorten recovery time for hospitalized COVID-19 patients and may reduce the need for respiratory support. 19 Similarly, proning (positioning patients to lie face down) improves oxygenation and can minimize the need for ventilation.<sup>20</sup> Laboratory engineered antibodies, or monoclonal antibodies (MABs), that mimic the immune system's ability to fight infection may help patients with mild to moderate COVID-19 (EUAs have been granted for select MABs).<sup>21,2</sup> Healthcare providers are also utilizing **convalescent plasma** (blood donated from recovered COVID-19 patients that contains disease fighting ABs)<sup>23</sup> and dexamethasone (a steroid that reduces inflammation and limits the overreaction of the immune system).<sup>24</sup> An EUA has been granted for convalescent plasma; its use is limited to treating hospitalized COVID-19 patients in the early stages of disease or those who are hospitalized and have impaired humoral immunity. <sup>25, 26</sup> As new data emerges, adjustments will be made to treatment strategies to ensure maximal efficacy.

#### COST

\$78,500:

The average cost for hospital care for an uninsured COVID-19 patient in the U.S.<sup>12</sup>


# \$2.6 trillion:

The estimated additional long-term costs for people who survive COVID-19 but have resulting long-term health damage.<sup>13</sup>

Which statement is closest to your view?

Statement A: The COVID-19 pandemic is a disruptive event and requires urgent refocusing of America's commitment to science.

Statement B: Things will get back to normal soon; we don't need increased efforts in science.



Source: A Research!America poll of U.S. adults conducted in partnership with Zogby Analytics in August 2020

# COVID-19

# Then. Now. Imagine.

At the onset of the pandemic, there were no known methods of preventing or treating COVID-19.

#### MOW

The FDA has granted emergency use authorization for several treatments and vaccines for COVID-19 and continues to evaluate emerging therapeutics.


#### **IMAGINE**

A world without COVID-19.

#### **Sex Differences and COVID-19**

Men tend to experience higher mortality rates and more severe symptoms from COVID-19. Women may mount a more adaptive and robust immune response than men, which could confer greater protection against the virus.<sup>27</sup> Men may also be more likely to downplay the high risk of infection and less likely to implement protective measures.<sup>28</sup> Leveraging research to inform intervention strategies is key to quelling COVID-19 gender disparities.

## COVID-19 Death Rates per 100,000 people, February 2021



- 1."About COVID-19." CDC.2020
- 2."Coronavirus (COVID-19) frequently asked questions". CDC. 2020 3."Symptoms of Coronavirus." CDC. 2020
- 4."People with Certain Medical Conditions". CDC. 2020
- 4. People with Lertain Redical Londitions. CULL. 2020
  5-Thultisystem Inflammatory Dissease.\*CDC.2020
  6-One in 20 people likely to suffer from Long CDVID, but who are they?. COVID Symptom Study. 2020
  7.The COVID-19 Racial Data Tracker. The COVID Tracking Project. 2020
  8.\*COVID-19 Advice for the Public.\* WHO. 2020
  9.\*Coronavirus in the U.S.: Latest Map and Case Count.\* NY Times. 2020.
  10.\*Coronavirus Disease 2019 Case Surveillance.\* CDC.2020
  11.\*About 80% of asymptomatic people with COVID-19 develop symptoms.\* Medscape.2020

- 12."The average cost of hospital care for COVID-19." Healthcare Finance. 2020 13. "The COVID-19 Pandemic and the \$16 Trillion Virus." JAMA.2020 14. "Why COVID-19 testing is the key to getting back to normal." NIH NIA. 2020
- 15. "Different types of COVID-19 tests explained". UC Davis Health. 2020 16. "Overview of Testing for SARS-CoV-2 (COVID-19). CDC.2020 17. "What's the science on DNA and RNA vaccines?". DW. 2020.
- 18."FDA's approval of Veklury (remdesivir) for the treatment of COVID-19-The Science of Safety and Effectiveness." FDA.2020
- 18. "Final report confirms remdesivir benefits for COVID-19."NIH. 2020 20."What is proning and how may it help COVID-19 Patients". Hackensack Meridian Health. 2020
- 21. "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19." FDA. 2020
- 22. Toronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19.\* FDA. 2020
  23. "Convalescent plasma therapy." Mayo Clinic. 2020
  24. "Coronavirus Disease (COVID-19): Dexamethasone." WHO. 2020
- 25. FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID-19 Treatment, Another Achievement in Administration's Fight Against Pandemic." FDA.2020 Another Achievement in Administration's Fight Against Pandemic, FDA 2020
  26. FDA In Brief: FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma to Reflect New
- Data." FDA. 2021
- 27.Takahashi et al. "Sex differences in immune responses that underlie COVID-19 disease outcome." Nature 2020 28.Okten et al. "Gender differences in preventing the spread of coronavirus." Behavioral Science and Policy. 2020

SOURCE: Statista U.S. COVID-19 death rate by state

Research!America 241 18th St S. Arlington, VA 22202 | 703-739-2577 www.researchamerica.org | info@researchamerica.org

The Albert and Mary Lasker Foundation is a founding partner in this series of fact sheets. www.laskerfoundation.org